SCHEMBL16045208

SCHEMBL16045208

COc1nc(NC(C)C)ncc1Br

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 5/20 0.47
▸ LRRK2 Q5S007 5/20 0.47
▸ IGF1R P08069 2/20 0.47
▸ MAPK8 P45983 2/20 0.47
▸ CHEK1 O14757 1/20 0.47
▸ AURKA O14965 1/20 0.47
▸ DAPK3 O43293 1/20 0.47
▸ PRKD3 O94806 1/20 0.47
▸ MAP4K4 O95819 1/20 0.47
▸ LCK P06239 1/20 0.47
▸ FYN P06241 1/20 0.47
▸ CSF1R P07333 1/20 0.47
▸ RET P07949 1/20 0.47
▸ PDGFRB P09619 1/20 0.47
▸ FGFR1 P11362 1/20 0.47
▸ LTK P29376 1/20 0.47
▸ GRK5 P34947 1/20 0.47
▸ MAPK9 P45984 1/20 0.47
▸ CDK8 P49336 1/20 0.47
▸ GSK3A P49840 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21823998 0.81 ADORA2A (0.46) KDRLRRK2CDK7CDK9ULK1
SCHEMBL21823999 0.81 ADORA2A (0.46) KDRLRRK2CDK7CDK9ULK1
SCHEMBL15142751 0.80 ULK1 (0.48) KDRLRRK2CHEK1PRKAA1NTRK2
SCHEMBL20836481 0.79 ULK1 (0.47) KDRLRRK2IGF1RCHEK1PTK2
SCHEMBL21873101 0.77 MEN1 (0.38) KDRLRRK2IGF1RMAPK8CHEK1
SCHEMBL2068179 0.76 ULK1 (0.45) KDRLRRK2IGF1RCLK4ULK1
SCHEMBL12413949 0.73 GAA (0.37) LRRK2ULK1JAK2
SCHEMBL13310454 0.72 IGF1R (0.62) KDRLRRK2IGF1RMAPK8CHEK1
SCHEMBL15142272 0.72 ULK1 (0.42) LRRK2ULK1ADORA2AADORA1BCL6
SCHEMBL1044527 0.72 KDM4E (0.42) KDRLRRK2IGF1RMAPK8CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023125812-A1 SUBSTITUTED PYRIMIDONE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF 上海海雁医药科技有限公司 2023-07-06 — — WO disclosed
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-11-23 — — US disclosed
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-11-23 — — US disclosed
CN-110461841-B Nitrogen heteroaryl derivative with CSF1R inhibitory activity, and preparation method and application thereof 上海和誉生物医药科技有限公司 2020-09-15 — — CN disclosed
CN-107311981-B 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activity 德西费拉制药有限责任公司 2020-05-29 — — CN disclosed
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-05-07 — — US disclosed
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-05-07 — — US disclosed
EP-3643715-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2020-04-29 — — EP disclosed
EP-3643715-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2020-04-29 — — EP disclosed
CN-110461841-A A kind of azepine aryl derivatives, preparation method and application with CSF1R inhibitory activity ABBISKO THERAPEUTICS CO LTD 2019-11-15 — — CN disclosed
EP-2968286-B1 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS LLC (US) 2017-09-13 — — EP disclosed
EP-2968286-A2 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES Deciphera Pharmaceuticals, LLC (US) 2016-01-20 — — EP disclosed
CN-105120864-A 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activity DECIPHERA PHARMACEUTICALS LLC 2015-12-02 — — CN disclosed
US-9181223-B2 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2015-11-10 — — US disclosed
WO-2014145025-A2 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-09-18 — — WO disclosed
US-20140275085-A1 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF CSF1R, CSF3R, FSHR KDR 533/4885LRRK2 407/4885IGF1R 81/4885
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof CSF1R, CSF3R, FSHR KDR 533/4885LRRK2 407/4885IGF1R 81/4885
US-20140275085-A1 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES CSF1R, KIT, CSF3R KDR 72/4885LRRK2 2623/4885IGF1R 144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback